Hot Topics

Poll

Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?:

Letter from KEI to USPTO regarding implementation of Beijing Treaty

On May 5, 2015, KEI sent a letter to the USPTO regarding the implementation of the Beijing Treaty on Audiovisual Performances. The letter focuses on concerns that KEI and others have expressed that a treaty implementation by amendment of 17 U.S. Code § 1101, regarding the "Unauthorized fixation and trafficking in sound recordings and music videos," creates problems, because the statute involves a right that is perpetual and not subject to normal copyright exceptions.

NIH refuses to give information about principals in company seeking exclusive license to HCV patents

The NIH provided these responses to four questions about the HCV drug patent license it is considering.

USTR's 2015 Special 301 List

Every year USTR issues a list of countries targeted to be subjected to trade pressures over their policies on intellectual property rights. This year's list was published on April 30, 2015. KEI has a copy of every version of the Special 301 list here: http://www.keionline.org/ustr/special301

USTR describes the list as follows:

The Special 301 Process

30 April 2015, KEI Seminar on Drug Pricing: Paul Grootendorst on Canadian Drug Pricing

Today, KEI hosted the first talk in a series of seminars on drug pricing. The seminar, conducted via video conference, focused on the Canadian approach to drug pricing. Each seminar in the series is intended to contribute to the discussion on drug pricing and how we can improve affordability and access to medicines. Paul Grootendorst began with a presentation (the slides are available here), before opening up the discussion to questions from those participating in the video conference.

California AB 463 (Pharmacetical Cost Transparency Act of 2015) Held Over as Two-Year Bill

Yesterday, under intense pressure from the powerful pharmaceutical industry lobby, California Assembly Member Dan Chiu withheld bill AB 463, the Pharmaceutical Cost Transparency Act of 2015. A vote on the bill had already been postponed for a week in order to allow Assembly Member Chiu more time to address various concerns raised by colleagues in the Health Committee.

Kassy Perry, speaking on behalf of ?, opposing AB 463, on transparency of drug R&D costs and subsidies

During the debate of California bill AB 463, on the Pharmaceutical Cost Transparency Act of 2015, Kassy Perry was using Twitter to attack the bill, posting links to and repeating pharmaceutical industry talking points. Who is Kassy Perry? A founder of Perry Communications, a Sacramento public relations and lobbying firm. This is her Twitter profile:

https://twitter.com/KassyPerry

Public Citizen, National Physicians Alliance, Other Civil Society Groups Write Letters in Support of California AB 463

In addition to the numerous groups and institutions that stood in support of AB 463 (Pharmaceutical Cost Transparency Act of 2015) at the California Assembly Health Committee hearing on April 21st, six civil society groups that we are aware of have submitted letters or statements in support of the bill.

In alphabetical order, these include:

1. American Medical Students Association (AMSA)
2. National Council of Asian Pacific Islander Physicians (NCAPIP)
3. National Physicians Alliance (NPA)
4. Public Citizen
5. Universities Allied for Essential Medicines (UAEM)

KEI Notes on California Assembly Health Committee Markup on AB 463 Pharmaceutical Cost Transparency Act of 2015

Yesterday (April 21,2015) the California Assembly held a Health Committee hearing to discuss various bills being offered, including Assembly Member Dan Chiu's AB 463, titled the Pharmaceutical Cost Transparency Act of 2015.

AB 463 calls for the pharmaceutical industry to annually report its costs for developing and manufacturing a drug (for any course of treatment over $10k). The bill seeks to provide audited information on R&D costs, a topic for which the industry often makes unsupported and exaggerated claims.

KEI Seminars on Drug Pricing: 30 April 2015, Prof. Paul Grootendorst on the Canadian approach to drug pricing

On Thursday, 30 April 2015, KEI will host the first talk in a series of seminars on drug pricing. The seminars will take place via video conference (hosted by KEI), and participation is welcome either by attending the presentation at KEI’s Washington, DC offices, or to the extent we are able, joining the digital conference.

OCR version of leaked EU document on : "A digital single market strategy for Europe"

Yesterday, Politico published this story:

Leaked digital single market’s ‘evidence file’ reveals Commission’s ambitions. Documents show policy came before evidence for cybersecurity measures.
By ZOYA SHEFTALOVICH 20/4/15, 1:29 PM CET Updated 21/4/15, 11:33 AM CET
(http://www.politico.eu/article/leaked-digital-single-market-strategy-evidence/)

WIPO CDIP 15: Statement of Brazil on evaluation of the Project on Open Collaborative Projects and IP-Based Models

On Tuesday, 21 April 2015, the 15th session of the World Intellectual Property Organization's (WIPO) Committee on Development and Intellectual Property (CDIP) considered the Evaluation Report for the Project on Open Collaborative Projects and IP-Based Models (CDIP/15/3). This project on open collaborate development models is based on Recommendation 36 of the WIPO which states,

Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?

The CA State Assembly Health Committee staff analysis of AB463; includes who supports and opposes

The California Assembly Health Committee has published an analysis of AB463, the Pharmaceutical Cost Transparency Act of 2015. The bill will be marked up by the committee on Tuesday (April 21). The analysis was written by Dharia McGrew. It recommends three amendments to the bill, and provides a discussion of the benefits of the required disclosures, with context, and describes the support and opposition. The staff report is attached, and below is a list of 33 groups supporting and 22 opposing the bill.

KEI statement to WHO 20th Expert Committee on the Selection and Use of Essential Medicines

Knowledge Ecology International (KEI) will present the following statement on 20 April 2015 to the Open Session of the 20th Expert Committee on the Selection and Use of Essential Medicines.

Statement of Knowledge Ecology International: WHO 20th Expert Committee on the Selection and Use of Essential Medicines, with specific focus on expanding access to new cancer drugs, when available at affordable prices

20 April 2015

Dear members of the WHO Expert Committee and the WHO secretariat,

State of California considers AB463, a bill to require disclosure of drug development costs, and more economic data

This is a bill that will see legislative action next week in California, and the bill has some momentum. This is the first time I have seen any government make an effort to have useful data on the economics drug drug development and pricing, and it provides a model that other governments may want to built upon.

A mark-up on the bill has been scheduled for Tuesday, April 21, 2015, in the Assembly Health Committee.

BILL NUMBER: AB 463
INTRODUCED BILL TEXT

INTRODUCED BY Assembly Member Chiu

FEBRUARY 23, 2015

Syndicate content